Annual Report 年報20212021 CHARACTERISTICS OF THE GEM OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE “STOCK EXCHANGE”)GEM has been positioned as a market designed to accommodate small and mid-sized companies to which a higher investment risk may be attached than other companies listed on the main board of the Stock Exchange. Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration.Given that the companies listed on the GEM are generally small and mid-sized companies, there is a risk that securities traded on the GEM may be more susceptible to high market volatility than securities traded on the Main Board of the Stock Exchange and no assurance is given that there will be a liquid market in the securities traded on the GEM.Hong Kong Exchanges and Clearing Limited and the Stock Exchange take no responsibility for the contents of this report, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this report.This annual report, for which the directors of Jilin Province Huinan Changlong Bio-pharmacy Company Limited and its subsidiaries (the “Group” and the “Directors”, respectively) collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the GEM of the Stock Exchange for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief, the information contained in this annual report is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this annual report misleading.香港聯合交易所有限公司（「聯交所」）GEM之特色GEM的定位，乃為中小型公司提供的市場，此等公司相比起其他在聯交所主板上市的公司帶有較高投資風險。有意投資的人士應了解投資於該等公司的潛在風險，並應經過審慎周詳的考慮後方作出投資決定。由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於聯交所主板買賣之證券承受較大的市場波動風險，同時無法保證在GEM買賣的證券會有高流通量的市場。香港交易及結算所有限公司及聯交所對本報告之內容概不負責，對其準確性或完整性亦不發表任何聲明，並表明不會就本報告全部或任何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。本年度報告乃遵照聯交所GEM證券上市規則的規定而提供有關吉林省輝南長龍生化藥業股份有限公司及其附屬公司（「本集 團」）的資料，本公司各董事（「董事」）願共同及個別對此負全責。董事經作出一切合理查詢後確認，就彼等所知及所信，本年度報告所載資料在所有重大方面均準確完整及並無誤導或欺詐成分，及概無遺漏其他事宜，致使本年度報告中任何聲明或本年度報告存在誤導成分。 CONTENTS目錄3–4Corporate Information公司資料5–7Chairman’s Statement主席報告8–14Management Discussion and Analysis管理層討論及分析15–19Biographical Details of Directors and Senior Management董事及高級管理層簡歷20–28Report of the Directors董事會報告書29–36Corporate Governance Report企業管治報告37Report of the Supervisory Committee監事會報告書38Environmental, Social and Governance Report環境、社會及管治報告39–47Independent Auditor’s Report獨立核數師報告書48Consolidated Statement of Profit or Loss andOther Comprehensive Income綜合損益及其他全面收益表49–50Consolidated Balance Sheet綜合資產負債表51Consolidated Statement of Changes in Equity綜合權益變動表52–53Consolidated Statement of Cash Flows綜合現金流量表54–123Notes to the Financial Statements財務報表附註124Five-Year Financial Summary五年財務摘要 CORPORATE INFORMATION公司資料吉林省輝南長龍生化藥業股份有限公司二零二一年年報3BOARD OF DIRECTORSExecutive DirectorsMr. Zhang Hong (Chairman)Mr. Zhang Xiao GuangMr. Zhao Bao GangMr. Wu Guo WenMr. Zhang YiMr. Xu Xiang FuIndependent Non-Executive DirectorsMr. Gao Qi PinMs. Tian JieMr. Bai Jun Gui (appointed on 23 September 2021)Mr. Gao Yong Cai (resigned on 5 August 2021)SUPERVISORSMr. Wang Ying XuMr. Yan Li YuMs. Qiao Xiao ChunCOMPLIANCE OFFICERMr. Zhang HongAUTHORIZED REPRESENTATIVESMr. Zhang HongMr. Zhao Bao GangAUDITORSReanda Lau & Au Yeung (HK) CPA LimitedCertified Public AccountantsHong KongAUDIT COMMITTEEMr. Bai Jun Gui (appointed on 23 September 2021)Mr. Gao Yong Cai (resigned on 5 August 2021)Ms. Tian JieMr. Gao Qi PinREMUNERATION COMMITTEEMr. Bai Jun Gui (appointed on 23 September 2021)Mr. Gao Yong Cai (resigned on 5 August 2021)Ms. Tian JieMr. Gao Qi PinMr. Zhang Hong董事會執行董事張弘先生（主席）張曉光先生趙寶剛先生吳國文先生張翼先生徐向夫先生獨立非執行董事高其品先生田傑女士白君貴先生 （於二零二一年九月二十三日獲委任）高永才先生 （於二零二一年八月五日辭任）監事王英旭先生鄢禮玉先生喬曉春女士監察主任張弘先生授權代表張弘先生趙寶剛先生核數師利安達劉歐陽（香港）會計師事務所有限公司執業會計師香港審核委員會白君貴先生 （於二零二一年九月二十三日獲委任）高永才先生 （於二零二一年八月五日辭任）田傑女士高其品先生薪酬委員會白君貴先生 （於二零二一年九月二十三日獲委任）高永才先生 （於二零二一年八月五日辭任）田傑女士高其品先生張弘先生 CORPORATE INFORMATION公司資料Jilin Province Huinan Changlong Bio-pharmacy Company LimitedANNUAL REPORT 20214公司秘書兼合資格會計師 莫世昌先生，CPA, FCCA提名委員會白君貴先生 （於二零二一年九月二十三日獲委任）高永才先生 （於二零二一年八月五日辭任）田傑女士高其品先生張曉光先生H股過戶登記處 香港證券登記有限公司香港皇后大道東183號合和中心17M主要往來銀行中國工商銀行輝南縣支行中國吉林省通化市香港主要營業地點香港九龍旺角彌敦道625及639號雅蘭中心辦公樓二期11樓1101–2室股份代號8049法定地址中國吉林省通化市輝南縣朝陽鎮北山街31號網址http://www.jlchanglong.comCOMPANY SECRETARY AND QUALIFIED ACCOUNTANTMr. Mok Sai Cheong Mark, CPA, FCCANOMINATION COMMITTEEMr. Bai Jun Gui (appointed on 23 September 2021)Mr. Gao Yong Cai (resigned on 5 August 2021)Ms. Tian J